Last reviewed 2026-04-19 · How we verify

GSBR-1290

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Phase 1 active Small molecule

At a glance

Generic name	GSBR-1290
Also known as	GSBR-1001290
Sponsor	Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Aleniglipron Phase 2 Body Composition Study (PHASE2)
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity (PHASE2)
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity (PHASE2)
Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (PHASE1, PHASE2)
A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants (PHASE1)
A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results